Complement contributes to antibody-mediated protection against repeated SHIV challenge

The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort has focused on optimizing neutralization breadth and potency, it remains unclear whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Benjamin S., Spencer, David A., Pandey, Shilpi, Ordonez, Tracy, Barnette, Philip, Yu, Yun, Gao, Lina, Dufloo, Jérémy, Bruel, Timothée, Schwartz, Olivier, Ackerman, Margaret E., Hessell, Ann J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193994/
https://www.ncbi.nlm.nih.gov/pubmed/37155897
http://dx.doi.org/10.1073/pnas.2221247120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193994/
https://www.ncbi.nlm.nih.gov/pubmed/37155897
http://dx.doi.org/10.1073/pnas.2221247120

Ejemplares similares